The clinical utility of the study of these processes in pancreatic adenocarcinoma is the possibility of using targeted therapies against them in the same way as breast, colon, or lung tumours, where monoclonal antibodies against vascular endothelial growth factor (VEGF) are used [50]. This evidence concerns the gene VEGFA and pancreatic adenocarcinoma.